26.08.2025 / Start-up News
Deal: Wenger Vieli advised InkVivo Technologies on its CHF 1.1m pre-seed financing round
Wenger Vieli advised InkVivo Technologies on all legal aspects of its CHF 1.1 million pre-seed financing round, led by TiVentures and Claves Investments with participation from experienced business angels. The proceeds will accelerate the development of InkVivo’s proprietary polymer-based drug formulation platform, including clinical work on lead anemia formulations and pipeline expansion.
InkVivo, a Swiss biotech spin-off from ETH Zurich, focuses on improving how medicines are formulated and delivered to enhance efficacy and patient outcomes. Operating on a B2B model, the company is advancing pilot collaborations with a pharmaceutical and a nutraceutical partner and is in further discussions with international industry leaders.
The team consisted of Michael Baier (Partner, Corporate/M&A), Dominique Mattmann (Senior Associate, Corporate/M&A) and Dario Schönbächler (Senior Associate, Corporate/M&A).